Structure Therapeutics
Clinical-stage biopharmaceutical company developing orally available small-molecule therapeutics for chronic metabolic, obesity-related and cardiopulmonary diseases. The organization applies structure-based drug design, GPCR structural biology, computational chemistry and data science to discover and advance oral small-molecule candidates from discovery through early clinical development. The company publishes peer-reviewed structural biology and translational pharmacology work and presents data at scientific conferences.
Industries
Nr. of Employees
medium (51-250)
Structure Therapeutics
Patents
Compounds and compositions for treating conditions associated with APJ receptor activity
US-11944622-B2
View Details
Compounds and compositions for treating conditions associated with APJ receptor activity
US-11944622-B2
View DetailsProducts
Clinical-stage portfolio of orally available small-molecule therapeutics
A portfolio of oral, non-peptide small-molecule candidates designed for chronic metabolic, obesity-related and cardiopulmonary conditions; advanced through preclinical studies into early clinical trials.
Clinical-stage portfolio of orally available small-molecule therapeutics
A portfolio of oral, non-peptide small-molecule candidates designed for chronic metabolic, obesity-related and cardiopulmonary conditions; advanced through preclinical studies into early clinical trials.
Expertise Areas
- Structure-based drug discovery for GPCRs
- Computational chemistry and physics-based modeling
- Medicinal chemistry and SAR optimization
- High-throughput structural biology and crystallography
Key Technologies
- Structure-based drug design
- Physics-based computational modeling
- Molecular dynamics / physics-driven methods
- X-ray crystallography
News & Updates
Company presentations scheduled at ObesityWeek 2026.
Announcement reporting positive clinical data across oral small-molecule programs for chronic weight management.
Company participation in investor conferences.
Company presentations scheduled at ObesityWeek 2026.
Announcement reporting positive clinical data across oral small-molecule programs for chronic weight management.
Company participation in investor conferences.